Compare Hormel Foods Corp (HRL) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Natera Inc. Common Stock — how do they compare? Hormel Foods Corp trades at $20.09 (market cap $10.57B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 5.4× Hormel Foods Corp's market cap, and Hormel Foods Corp pays a 6.09% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Natera Inc. Common Stock for 0 Days on average.
| HRL | NTRA | |
|---|---|---|
Market Cap | $10.57B | $57.03B |
Volume | 4,381,202 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $425.64 |
52-Week Low | $19.19 | $179.42 |
Typical Hold Time | 99 Days | 0 Days |
Enterprise Value | $12.56B | $56.18B |
Dividend Yield | 6.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.81, up 2.64% today, with a mixed technical outlook showing bearish moving averages but oversold RSI signals. The company reported Q2 2026 EPS of $0.37, beating estimates, but net income margin has declined to 2.82% in 2026 from 6.75% in 2024. Recent news highlights the $1.06 billion Brakebush acquisition to expand its chicken business, while the dividend yield remains a key attraction with 60 consecutive years of increases.
The stock offers a compelling dividend history but faces growth challenges with shrinking profit margins and elevated P/E of 30.98. Analyst consensus is cautious with a $25 price target, and the acquisition integration poses execution risk. Upside depends on successful cost management and foodservice expansion, while margin pressure and high payout ratios remain headwinds.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
